Achievement of pCR was associated with a numerically lower risk of death and recurrence (OS: HR 0.56, 95% CI 0.24-1.30; DFS: HR 0.51, 95% CI 0.22-1.16).<h4>Conclusion</h4>The neoadjuvant FinHer protocol resulted in a pCR rate of 30% in locally advanced HER2-positive breast cancer. Here, ERBB2 is linked to breast carcinoma.